Leo licensed tralokinumab from AstraZeneca in 2016 for use in dermatology shortly before it failed as an asthma treatment. The Danish firm shares rights to the drug with Almirall .

The ECZTRA (ECZema TRAlokinumab trial No.6) was a randomised, double-blind, placebo-controlled, parallel-group, multinational 52-week trial, including a total of 301 patients aged 12 to 17 ...